Curt Oltmans

Curt Oltmans has extensive experience in the legal field. Curt currently holds the roles of Chief Legal Officer and SVP, General Counsel & Corporate Secretary at Fulcrum Therapeutics, starting in November 2020. Curt is also a Director on the Board of Directors of Avenue Therapeutics since April 2021. Prior to this, they served as VP, Litigation at DaVita from June 2019 to November 2020. From August 2017 to March 2019, they held the position of EVP, General Counsel & Corporate Secretary at Array BioPharma Inc. In addition, they worked as a Sr attorney at Consultant legal for a brief period in August 2017. From November 2012 to August 2017, they were the Corporate Vice President at Novo Nordisk Inc., where they provided legal, patent, and risk management expertise. Before that, they were the Deputy General Counsel at Novo Nordisk Pharmaceuticals from June 2005 to August 2017. Curt Oltmans began their legal career at Eli Lilly in February 1992, where they worked in the litigation group and provided FDA advice for the antibiotics group. Curt later served as General Counsel for Central & Eastern Europe, Africa, and the Middle East from 1998 to 2003, based in Europe.

Curt Oltmans completed their education from 1985 to 1988, earning a JD degree in law from the University of Nebraska-Lincoln.